498 related articles for article (PubMed ID: 35085851)
41. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
[TBL] [Abstract][Full Text] [Related]
42. Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19.
Chang A; Yu J
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215973
[TBL] [Abstract][Full Text] [Related]
43. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
[TBL] [Abstract][Full Text] [Related]
44. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
45. Scent of a vaccine.
Lund FE; Randall TD
Science; 2021 Jul; 373(6553):397-399. PubMed ID: 34437109
[No Abstract] [Full Text] [Related]
46. Audio Interview: Aspects of Covid-19 Immunity.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Aug; 385(8):e31. PubMed ID: 34407350
[No Abstract] [Full Text] [Related]
47. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.
Saunders KO; Lee E; Parks R; Martinez DR; Li D; Chen H; Edwards RJ; Gobeil S; Barr M; Mansouri K; Alam SM; Sutherland LL; Cai F; Sanzone AM; Berry M; Manne K; Bock KW; Minai M; Nagata BM; Kapingidza AB; Azoitei M; Tse LV; Scobey TD; Spreng RL; Rountree RW; DeMarco CT; Denny TN; Woods CW; Petzold EW; Tang J; Oguin TH; Sempowski GD; Gagne M; Douek DC; Tomai MA; Fox CB; Seder R; Wiehe K; Weissman D; Pardi N; Golding H; Khurana S; Acharya P; Andersen H; Lewis MG; Moore IN; Montefiori DC; Baric RS; Haynes BF
Nature; 2021 Jun; 594(7864):553-559. PubMed ID: 33971664
[TBL] [Abstract][Full Text] [Related]
48. Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2.
Li L; Wang M; Hao J; Han J; Fu T; Bai J; Tian M; Jin N; Zhu G; Li C
Int J Biol Macromol; 2021 Nov; 190():409-416. PubMed ID: 34499954
[TBL] [Abstract][Full Text] [Related]
49. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
Front Immunol; 2021; 12():771242. PubMed ID: 34880867
[TBL] [Abstract][Full Text] [Related]
50. On the road to ending the COVID-19 pandemic: Are we there yet?
Case JB; Winkler ES; Errico JM; Diamond MS
Virology; 2021 May; 557():70-85. PubMed ID: 33676349
[TBL] [Abstract][Full Text] [Related]
51. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines.
Fraser R; Orta-Resendiz A; Mazein A; Dockrell DH
Trends Mol Med; 2023 Apr; 29(4):255-267. PubMed ID: 36764906
[TBL] [Abstract][Full Text] [Related]
52. Recombinant protein vaccines, a proven approach against coronavirus pandemics.
Pollet J; Chen WH; Strych U
Adv Drug Deliv Rev; 2021 Mar; 170():71-82. PubMed ID: 33421475
[TBL] [Abstract][Full Text] [Related]
53. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
Du Y; Xu Y; Feng J; Hu L; Zhang Y; Zhang B; Guo W; Mai R; Chen L; Fang J; Zhang H; Peng T
Vaccine; 2021 Apr; 39(16):2280-2287. PubMed ID: 33731271
[TBL] [Abstract][Full Text] [Related]
54. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
Kim E; Weisel FJ; Balmert SC; Khan MS; Huang S; Erdos G; Kenniston TW; Carey CD; Joachim SM; Conter LJ; Weisel NM; Okba NMA; Haagmans BL; Percivalle E; Cassaniti I; Baldanti F; Korkmaz E; Shlomchik MJ; Falo LD; Gambotto A
Eur J Immunol; 2021 Jul; 51(7):1774-1784. PubMed ID: 33772778
[TBL] [Abstract][Full Text] [Related]
55. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
Front Immunol; 2022; 13():858904. PubMed ID: 35592324
[TBL] [Abstract][Full Text] [Related]
56. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
Li Q; Wang J; Tang Y; Lu H
Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
[TBL] [Abstract][Full Text] [Related]
57. Recent advances in respiratory immunization: A focus on COVID-19 vaccines.
He X; Chen X; Wang H; Du G; Sun X
J Control Release; 2023 Mar; 355():655-674. PubMed ID: 36787821
[TBL] [Abstract][Full Text] [Related]
58. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
59. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response.
Chen L; Zhang H; Li M; Wu B; Zhang Z; Gong R
Front Immunol; 2022; 13():1005321. PubMed ID: 36466882
[TBL] [Abstract][Full Text] [Related]
60. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
Xiao L; Yu W; Shen L; Yan W; Qi J; Hu T
ACS Appl Mater Interfaces; 2023 Aug; 15(30):35895-35905. PubMed ID: 37466148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
